# Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

> **NCT05394233** · PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 20 (estimated)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer
- EGFR Gene Mutation

## Interventions

- **DRUG:** Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed

## Key facts

- **NCT ID:** NCT05394233
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394233, "Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05394233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*